<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413854</url>
  </required_header>
  <id_info>
    <org_study_id>eudraCT number 2010-021024-10</org_study_id>
    <nct_id>NCT01413854</nct_id>
  </id_info>
  <brief_title>Diclofenac add-on to Treatment as Usual for Suicidal Patients</brief_title>
  <official_title>&quot;Antiinflammatoriska läkemedels Effekt för Att Minska Suicidalitet Hos Deprimerade Patienter Som Nyligen Har Gjort självmordsförsök&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether diclofenac is effective in the treatment of
      depressed patients with a recent suicide attempt.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will start with a feasibility study including treatment of 10 patients with
      diclofenac.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suicide Assessment Scale (differences in scores before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Rating Scale (differences in scores before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt Impulsiveness Scale (differences in scores before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg depression Ratin scale (changes in suicidality item before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Rating Scale (changes in concentration item before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive Psychopathological Rating Scale (changes in aggressive feelings item before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive Psychopthological Rating Scale (changes in fatigue item before and after treatment)</measure>
    <time_frame>four weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression Suicidal</condition>
  <arm_group>
    <arm_group_label>diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>One tablet two times daily during four weeks</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>One tablet two times daily during four weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>50 mg, two times daily (oral adm.) during four weeks</description>
    <arm_group_label>diclofenac</arm_group_label>
    <other_name>50 mg, two times daily (oral adm.) during four weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Depressive disorder

          -  Montgomery Asberg Rating Scale Score more than 20 p.

          -  Recent suicide attempt (Treated as inpatient due to a recent suicide attempt)

          -  Informed consent

          -  Competence to give informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Serious somatic disease e.g. serious heart, vascular, hepatic, kidney, pulmonary,
             intestinal, endocrine, haematological or neurological diseases

          -  Ongoing substance abuse

          -  Schizophrenia or other psychotic disorders

          -  Ongoing psychosis

          -  Risk factors for cardiovascular events

          -  Ulcer or gastrointestinal bleeding

          -  Ongoing Electroconvulsive therapy

          -  Previous allergic reaction to NSAID, acetylsalicylic acid, sulfonamides or the
             diclofenac or sugar pill content

          -  Galactose intolerance, lactase deficiency or glucose-galactose malabsorption

          -  Ongoing treatment with warfarin or other anticoagulants

          -  Ongoing treatment with ACE inhibitors or angiotensin II antagonists Ongoing treatment
             with drugs known to effect the immune system Ongoing treatment with rifampicin,
             carbamazepine or barbiturates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åsa Westrin, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatry Skane</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Åsa Westrin, Associate professor</name_title>
    <organization>Lund University</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

